Importance Measurable residual disease (MRD) refers to neoplastic cells that cannot be
detected by standard cytomorphologic analysis. In patients with acute myeloid leukemia …

For several decades, few substantial therapeutic advances have been made for patients
with acute myeloid leukaemia. However, since 2017 unprecedented growth has been seen …

Measurable residual disease (MRD; previously termed minimal residual disease) is an
independent, postdiagnosis, prognostic indicator in acute myeloid leukemia (AML) that is …

The first edition of the European LeukemiaNet (ELN) recommendations for diagnosis and
management of acute myeloid leukemia (AML) in adults, published in 2010, has found …

New high-dimensional, single-cell technologies offer unprecedented resolution in the
analysis of heterogeneous tissues. However, because these technologies can measure …

Importance Tests that predict outcomes for patients with acute myeloid leukemia (AML) are
imprecise, especially for those with intermediate risk AML. Objectives To determine whether …

The past 40 years have witnessed major advances in defining the cytogenetic aberrations,
mutational landscape, epigenetic profiles, and expression changes underlying …

Current risk algorithms are primarily based on pre-treatment factors and imperfectly predict
outcome in acute myeloid leukemia (AML). We introduce and validate a post-treatment …

Diagnosis, treatment, response monitoring, and outcome of pediatric acute myeloid
leukemia (AML) have made enormous progress during the past decades. Because AML is a …

Purpose We investigated the effect on outcome of measurable or minimal residual disease
(MRD) status after each induction course to evaluate the extent of its predictive value for …